Avalyn Pharma News and Activities

Acquisition, funding and merger involving Avalyn Pharma.

• Avalyn Pharma has just announced a $300 Million fundraising (posted on April 30 2026).
• Avalyn Pharma has filed its IPO. Its stock ticker will be IPF. (posted on April 9 2026).

View the org chart displaying its 32 main executives

Most searched biographies at Avalyn Pharma

• Lyn Baranowski, Chief Executive Officer
• Erin Lavelle, Director
• Ketan Patel, Director

Popular executive movements at Avalyn Pharma

• Frank Salisbury has joined the company as Senior Vice President, Commercial  (posted on April 27 2026).
• Adam Golden has joined the company as General Counsel and Head of Business Development  (posted on April 27 2026).
• Jon Congleton has joined the company as Director  (posted on April 7 2026).

Click here to view some more movements at Avalyn Pharma

Create your alert
to follow the executive moves at Avalyn Pharma.

Avalyn Pharma has 2,424 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• The new name of EG 427 is Cyllene Therapeutics. (posted on July 9 2026).
• Opthea will change its company name to Ceryvyn Therapeutics on Jul 9, 2026. (posted on July 9 2026).
• Tissium has just announced a $60 Million fundraising (posted on July 8 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Carl Gordon - Director at Odyssey Therapeutics
• Jan Van de Winkel - President and Chief Executive Officer at Genmab

Learn more about the Biotechnology industry

Press releases by Avalyn Pharma

• Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis | Wed, 06/17/2026 - 08:00
• Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights | Wed, 06/03/2026 - 07:00
• Avalyn to Participate in the Jefferies Global Healthcare Conference | Wed, 05/27/2026 - 08:00
• Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for Rheumatology 2026 | Thu, 05/21/2026 - 08:00
• Avalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference | Tue, 05/05/2026 - 16:01
• Avalyn Announces Pricing of Upsized Initial Public Offering | Wed, 04/29/2026 - 21:01
• Avalyn Strengthens Leadership Team to Support Long-Term Growth with Appointments of Industry Leaders Adam Golden and Frank Salisbury | Mon, 04/27/2026 - 08:00
• Avalyn Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares | Fri, 05/01/2026 - 16:01
• Avalyn Strengthens Leadership Team to Support Long-Term Growth with Appointments of Industry Leaders Adam Golden and Frank Salisbury
• Avalyn Appoints Jon Congleton, Seasoned Biopharmaceutical Executive, to its Board of Directors
• View more press releases Close

Social media about Avalyn Pharma

• Avalyn Pharma on Wikipedia, Google News & Yahoo Finance
• Avalyn Pharma on LinkedIn, X (Twitter) & YouTube